BioCentury
ARTICLE | Product Development

Phase II data bring Blueprint closer to major market expansion for Ayvakit

March 17, 2020 12:10 AM UTC
Updated on Mar 21, 2020 at 3:44 AM UTC

With positive initial data for Ayvakit in indolent systemic mastocytosis, Blueprint is moving into position to expand its only approved drug into a much larger patient population while sticking to its strategy of focusing on genetically defined subsets of cancer and rare diseases.

Blueprint Medicines Corp. (NASDAQ:BPMC) presented data from the first, dose-finding part of its Phase II PIONEER trial at the American Academy of Allergy, Asthma & Immunology (AAAAI) virtual forum on Monday, showing that the lowest dose of Ayvakit avapritinib reduced symptoms and improved quality of life...